Stockreport

Nuvectis' NXP800 gains FDA ODD for cancer treatment [Yahoo! Finance]

Nuvectis Pharma, Inc.  (NVCT) 
PDF domain-containing protein 1a (ARID1a)-deficient ovarian, fallopian tube and primary peritoneal cancers. ODD status is granted by the US regulator for treatments of rar [Read more]